Actively Recruiting
Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit
Led by University Hospital, Montpellier · Updated on 2024-03-29
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Severe infections in pediatric intensive care unit are not uncommon. Historically, the diagnosis of hereditary (primary) immune deficiency required a combination of recurrent clinical signs and biological stigmas. This paradigm is currently being questioned, and grows the hypothesis of a potential underlying genetic susceptibility in any severe infection. To date, the proportion of severe infections explained by an underlying immune deficiency is unknown. The aim of this prospective study is to assess the incidence of primary immune deficiencies in children with severe infection, regardless of their etiology.
CONDITIONS
Official Title
Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age less than 16 years
- Actual age over 3 months for full-term infants and over 3 months for former preterm infants
- Documented severe infection (bacterial, viral, fungal) at University Hospital Center of Montpellier, Toulouse, or Marseille
- Infection requiring hospitalization in pediatric intensive care for more than 24 hours, including meninges or brain lesions, pleuro-pneumopathy, infection with sepsis or opportunistic germs, septic shock, encephalitis, or encephalomyelitis of infectious origin
- Child covered by a social security system
- Parental or legal guardian consent obtained
You will not qualify if you...
- Undocumented severe infections
- Acute bronchiolitis
- Admission for isolated SRV bronchiolitis without complications
- Previous conditions explaining infection or ICU stay such as known immune deficiency, burns, epilepsy risk factors, pneumonia from swallowing disorders, tracheotomy, chronic lung disease, asthma, meningitis due to cochlear implants or blood-brain barrier breach, deep infection on implants or within 48 hours after surgery, cardiovascular decompensation, or other chronic conditions contributing to infection
- Inability to obtain parental or legal guardian consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Uhmontpellier
Montpellier, France, 34295
Actively Recruiting
Research Team
E
Eric JEZIORSKI
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here